Press release
May 7, 2025
Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments
Barinthus Biotherapeutics plc. (BRNS)
Highly differentiated immunotherapy for celiac disease (VTP-1000) in the clinic, with Phase 1 single ascending dose readout from AVALON expected in the third quarter of 2025; Initiation of VTP-1000 multiple ascending dose expected in the second half of 2025; Encouraging results from HBV003 and